摘要
目的观察miR—340蛋白的表达在三阴乳腺癌(triple—negative breast cancer,TNBC)的发生,发展和转移中的作用。方法选择2006年1月~2012年12月在我院行乳腺癌根治的患者60例,根据免疫组织化学的雌激素受体(estrogen receptor,ER),孕激素受体(progesterone receptor,PR)和人表皮生长因子的受体(human epidermal growth factor receptor,HER-2)表达,分为三阴性乳腺癌(triple negative breast cancer,TNBC)33例和非TNBC 27例,同时选择同期乳腺癌癌旁组织15例,运用免疫组化检测miR-340蛋白的表达。结果癌旁组织的miR-340阳性表达率为73.33%,TNBC为51.52%,而非TNBC为29.63%,三组表达差异有统计学意义(X^2=7.671,P<0.05)。miR-340蛋白的表达在TNBC和非TNBC患者中与年龄,月经状态和肿瘤直径差异无统计学意义,而miR-340蛋白的表达与TNBC的临床分期和淋巴结是否转移具有明显的相关性(P<0.05)。结论 miR-340参与了TNBC的发生发展,可能成为TNBC治疗的目的基因之一。
Objective To investigate the relationship among the expression of miR-340 protein, occurrence, development and metastasis in triple-negative breast cancer (TNBC). Method 60 patients with breast cancer, from January 2006 to December 2012, according to the immunohistochemistry expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER-2), were divided into TNBC (33 patients) and non-TNBC (27 patients), and the breast cancer tissues (15 patients) were also selected at the same period, and the expression of miR-340 protein were detected by the immunohistochemistry. Results The positive expression of miR-340 protein was 73.33%in adjacent tissues of breast cancer, 51.52%in TNBC, 29.63%non-TNBC, the expression differences of each group were statistically significant(χ2=7.671,P<0.05). The expression of miR-340 protein in TNBC and non-TNBC patients were no significant difference in age, menopausal status and tumor size;while there were obvious correlation among clinical stage, lymph node metastasis and protein expression of miR-340 in TNBC(P<0.05). Conclusion The gene of miR-340 involves in the occurrence, development and metastasis of TNBC, they would be one of the purposes gene therapy in TNBC.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第1期72-73,共2页
Chinese Journal of Biochemical Pharmaceutics
